TW470750B - Reversible cysteine protease inhibitors - Google Patents

Reversible cysteine protease inhibitors Download PDF

Info

Publication number
TW470750B
TW470750B TW085104392A TW85104392A TW470750B TW 470750 B TW470750 B TW 470750B TW 085104392 A TW085104392 A TW 085104392A TW 85104392 A TW85104392 A TW 85104392A TW 470750 B TW470750 B TW 470750B
Authority
TW
Taiwan
Prior art keywords
compound
formula
group
phenyl
patent application
Prior art date
Application number
TW085104392A
Other languages
English (en)
Chinese (zh)
Inventor
James T Palmer
David Rasnick
Jeffrey Lee Klaus
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Application granted granted Critical
Publication of TW470750B publication Critical patent/TW470750B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215Radicals derived from nitrogen analogues of carbonic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/26Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1016Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
TW085104392A 1995-03-24 1996-04-12 Reversible cysteine protease inhibitors TW470750B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40999695A 1995-03-24 1995-03-24

Publications (1)

Publication Number Publication Date
TW470750B true TW470750B (en) 2002-01-01

Family

ID=23622800

Family Applications (1)

Application Number Title Priority Date Filing Date
TW085104392A TW470750B (en) 1995-03-24 1996-04-12 Reversible cysteine protease inhibitors

Country Status (15)

Country Link
EP (1) EP0817778A1 (ko)
JP (1) JPH11503417A (ko)
KR (1) KR19980703261A (ko)
CN (1) CN1071751C (ko)
AU (1) AU713492B2 (ko)
CA (1) CA2216151A1 (ko)
CZ (1) CZ298197A3 (ko)
IL (1) IL117638A0 (ko)
MY (1) MY113489A (ko)
NO (1) NO311573B1 (ko)
NZ (1) NZ305626A (ko)
PL (1) PL322409A1 (ko)
TW (1) TW470750B (ko)
WO (1) WO1996030353A1 (ko)
ZA (1) ZA962336B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2251714A1 (en) 1996-04-22 1997-10-30 Massachusetts Institute Of Technology Suppression of immune response via inhibition of cathepsin s
EP0934293A1 (en) * 1996-07-30 1999-08-11 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity
DE19817461A1 (de) * 1998-04-20 1999-10-21 Basf Ag Neue substituierte Benzamide, deren Herstellung und Anwendung
JP2002538151A (ja) 1999-03-02 2002-11-12 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド カテプシンの可逆的インヒビターとして有用な化合物
DE60003702T2 (de) * 1999-09-13 2004-04-22 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyclische verbindungen als reversible inhibitoren von cysteinproteasen
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
CA2387805C (en) 1999-11-18 2012-08-28 Corvas International, Inc. Nucleic acids encoding endotheliases, endotheliases and uses thereof
US7700341B2 (en) 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
ATE324372T1 (de) 2000-08-14 2006-05-15 Ortho Mcneil Pharm Inc Substituierte pyrazole
RU2317988C2 (ru) 2000-08-14 2008-02-27 Орто-Макнейл Фармасьютикал, Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, применение фармацевтической композиции и способ ингибирования активности катепсина s
PT1309591E (pt) 2000-08-14 2007-04-30 Ortho Mcneil Pharm Inc Pirazoles substituídos
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US6579896B2 (en) 2000-09-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Method for treating allergies using substituted pyrazoles
WO2002048097A1 (en) * 2000-12-12 2002-06-20 Corvas International, Inc. Compounds, compositions and methods for treatment of parasitic infections
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
EP1436255A1 (en) * 2001-09-14 2004-07-14 Aventis Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
WO2003024923A1 (en) * 2001-09-14 2003-03-27 Axys Pharmaceuticals, Inc. Sulfonamide compounds as protease inhibitors
KR20050044497A (ko) 2001-11-14 2005-05-12 아벤티스 파마슈티칼스 인크. 올리고펩티드 및 카텝신 s 억제제로서 이를 포함하는조성물
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
SG191591A1 (en) 2008-05-21 2013-07-31 New World Lab Inc Selective caspase inhibitors and uses thereof
WO2010133000A1 (en) 2009-05-21 2010-11-25 New World Laboratories Inc. Selective caspase inhibitors and uses thereof
US8895497B2 (en) 2009-12-04 2014-11-25 Dcb-Usa, Llc Cathepsin S inhibitors
EP2697246B1 (en) 2011-04-15 2018-03-07 Genesis Technologies Limited Selective cysteine protease inhibitors and uses thereof
KR101309578B1 (ko) * 2011-05-06 2013-09-17 연세대학교 산학협력단 시스테인 프로테아제 선택성을 갖는 다이타이로신 화합물 및 이를 이용한 시스테인 프로테아제의 검출방법
KR101385855B1 (ko) * 2012-10-16 2014-04-22 이동익 카뎁신 검출용 다이아로마틱 아미노산 기질
US20200361967A1 (en) * 2018-01-19 2020-11-19 Osaka Soda Co., Ltd. Organosilicon compound and rubber composition comprising the same
EP3553521A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Gingivitis diagnostic methods, uses and kits

Also Published As

Publication number Publication date
MY113489A (en) 2002-03-30
WO1996030353A1 (en) 1996-10-03
NZ305626A (en) 2000-01-28
CN1184472A (zh) 1998-06-10
EP0817778A1 (en) 1998-01-14
NO311573B1 (no) 2001-12-10
AU713492B2 (en) 1999-12-02
JPH11503417A (ja) 1999-03-26
CN1071751C (zh) 2001-09-26
AU5367496A (en) 1996-10-16
NO974403D0 (no) 1997-09-23
CZ298197A3 (cs) 1998-03-18
ZA962336B (en) 1996-07-31
NO974403L (no) 1997-11-17
PL322409A1 (en) 1998-01-19
CA2216151A1 (en) 1996-10-03
IL117638A0 (en) 1996-07-23
KR19980703261A (ko) 1998-10-15

Similar Documents

Publication Publication Date Title
TW470750B (en) Reversible cysteine protease inhibitors
US5776718A (en) Reversible protease inhibitors
ES2561753T3 (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
US6030946A (en) Reversible cysteine protease inhibitors
AU2015265820C1 (en) Cyclopropylamine compounds as histone demethylase inhibitors
AU715049B2 (en) N-substituted piperazine nonoates
ES2298837T3 (es) Derivados del acido fosfinico, inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer.
JPH04217652A (ja) 酢酸誘導体、その製造法、それを含む製薬調製剤、及びその製薬調製剤製造への利用
JPH0859610A (ja) ファルネシル蛋白質トランスフェラーゼの抑制剤
JPH04226913A (ja) オキザリルアミノ酸誘導体およびそれを含有する医薬
SK64993A3 (en) Hydroxamic acid derivatives, method of their preparation and medicaments with their content
DE60221508T2 (de) Aminosäurederivate als hiv-protease-inhibitoren
JPH06510017A (ja) 芳香族スルホンアミド化合物、阻害剤及びそれを含有する医薬組成物
DE4443390A1 (de) Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
KR20090008441A (ko) 신경원인성 통증을 억제하는 피롤리딘 유사체 및 그 제조 방법
JPS6319506B2 (ko)
EP0333000B1 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
JP2023538768A (ja) 緑膿菌病原性因子LasBの阻害剤
JP4601249B2 (ja) ペプチド誘導体及びその薬学的に許容される塩、その製造方法並びにその用途
Erdal et al. Hydroxyethylene isosteres of selective neuronal nitric oxide synthase inhibitors
JPS6298A (ja) ジペプチド誘導体およびこれを含有する降圧剤
JP2022538913A (ja) ネプリライシン(nep)阻害剤、特にアミノペプチダーゼn(apn)及びネプリライシン(nep)の混合阻害剤としてのn-ホルミルヒドロキシルアミン
WO2023107481A1 (en) Amide-containing lonp1 inhibitor compounds, uses and methods
WO1999012912A1 (en) Thiourea derivatives or non-toxic salts thereof for inhibitng ras-transformed cell growth
TW203008B (ko)